-+ 0.00%
-+ 0.00%
-+ 0.00%

Taysha Gene Therapies to present REVEAL Phase 1/2 data for Rett gene therapy TSHA-102 at 2026 IRSF meeting

PUBT·06/25/2026 20:01:24
Listen to the news
Taysha Gene Therapies to present REVEAL Phase 1/2 data for Rett gene therapy TSHA-102 at 2026 IRSF meeting
  • Taysha Gene Therapies flagged new updates for TSHA-102 in Rett syndrome ahead of the 2026 IRSF scientific meeting, June 29 to July 1.
  • Longer-term data from REVEAL Part A were already disclosed, showing broad functional improvements that deepened over at least 12 months.
  • Additional REVEAL Part A safety and efficacy results will be presented June 30, spanning pediatric plus adolescent/adult cohorts.
  • A natural history analysis found a developmental plateau after age 6, supporting a stable population for the planned REVEAL pivotal trial.
  • New validation work supports the developmental milestone assessment as an FDA-supported primary endpoint for single-arm interventional studies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606251601PRIMZONEFULLFEED9752893) on June 25, 2026, and is solely responsible for the information contained therein.